Advanced

Prevalence and clinical correlations of antibodies against six beta 2-glycoprotein-I-related peptides in the antiphospholipid syndrome

Shoenfeld, Y; Krause, I; Kvapil, F; Sulkes, J; Lev, S; von Landenberg, P; Font, J; Zaech, J; Cervera, R and Piette, JC, et al. (2003) In Journal of Clinical Immunology 23(5). p.377-383
Abstract
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our... (More)
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our results point to a heterogeneous activity of antiphospholipid Abs in APS patients, directed, often concurrently, against various epitopes of the beta2GPI molecule. Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
systemic lupus, antiphospholipid syndrome, synthetic peptides, autoimmunity, erythematosus
in
Journal of Clinical Immunology
volume
23
issue
5
pages
377 - 383
publisher
Springer
external identifiers
  • pmid:14601646
  • wos:000184844500006
  • scopus:0042832999
ISSN
0271-9142
DOI
10.1023/A:1025321617304
language
English
LU publication?
yes
id
515fca77-03a2-4228-8ea8-fbaf8d973ab0 (old id 303464)
date added to LUP
2007-09-21 12:51:20
date last changed
2018-05-29 12:25:31
@article{515fca77-03a2-4228-8ea8-fbaf8d973ab0,
  abstract     = {Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our results point to a heterogeneous activity of antiphospholipid Abs in APS patients, directed, often concurrently, against various epitopes of the beta2GPI molecule. Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes.},
  author       = {Shoenfeld, Y and Krause, I and Kvapil, F and Sulkes, J and Lev, S and von Landenberg, P and Font, J and Zaech, J and Cervera, R and Piette, JC and Boffa, MC and Khamashta, MA and Bertolaccini, ML and Hughes, GRV and Youinou, P and Meroni, PL and Pengo, V and Alves, JD and Tincani, A and Szegedi, G and Lakos, G and Sturfelt, Gunnar and Jönsen, Andreas and Koike, T and Sanmarco, M and Ruffatti, A and Ulcova-Gallova, Z and Praprotnik, S and Rozman, B and Lorber, M and Vriezman, VB and Blank, M},
  issn         = {0271-9142},
  keyword      = {systemic lupus,antiphospholipid syndrome,synthetic peptides,autoimmunity,erythematosus},
  language     = {eng},
  number       = {5},
  pages        = {377--383},
  publisher    = {Springer},
  series       = {Journal of Clinical Immunology},
  title        = {Prevalence and clinical correlations of antibodies against six beta 2-glycoprotein-I-related peptides in the antiphospholipid syndrome},
  url          = {http://dx.doi.org/10.1023/A:1025321617304},
  volume       = {23},
  year         = {2003},
}